Prognostic Impact of Cardiac Imaging During Suspected Immune Checkpoint Inhibitor Myocarditis

Myocarditis Clinical Trial

— IMMUNOIMAGING  

Official title:

Prognostic Impact of Cardiac Imaging During Suspected Immune Checkpoint Inhibitor Myocarditis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05086146
• Other study ID #: 2020-63
• Secondary ID: 2020-A03384-35
• Status: Recruiting
• Start date: August 10, 2021
• Est. completion date: March 2024

Study information

• Verified date: October 2021
• Source: Assistance Publique Hopitaux De Marseille
• Contact: DEHARO PIERRE
• Phone: (0)4 91 96 86 83
• Email: pierre.deharo[@]ap-hm.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

It consists of evaluating the advantage of routine detection of phIGFBP-1 to reduce the total duration of hospitalization for patients with a risk of preterm labor before 32 weeks of gestation without increasing the number of preterm labour.

Description:

Patient with a risk of preterm labor (ultrasound cervical length < 25 mm +/- described or recorded uterine contractions) before 32 weeks of gestation will be hospitalized to receive tocolytic drugs and antenatal corticosteroid therapy according to the investigators gold standard protocol. After 48 hours, the participants will be assessed by examination, external tocodynamometry and the measure of cervical length by ultrasound. Stabilized patients will be included and randomized into 2 groups of 210 patients each. The first group "A" will benefit from the standard protocol (extended hospitalization of 2 or 4 days according to the clinical and ultrasound assessment); whereas the second group, "B", will have the benefit of the detection of phIGFBP-1.If the result proves negative, patients could be discharged early at day 2. In the case of a positive result, patients will follow the standard procedure because of the low positive predictive value of the test. The main outcome is the total duration of hospitalization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 2024
• Est. primary completion date: September 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

All patients affiliated to the French social security system will be eligible, after signing a consent form, and presenting the following criteria

• Introduction within the last 3 months of at least one of the following ICIs:

nivolumab, pembrolizumab, cemiplimab, avelumab, atezolizumab, ipilimumab, tremelimumab, durvalumab.

• Suspicion of myocarditis defined by the presence of at least one of the following

criteria adapted from the European Society of Cardiology guidelines:

• Symptomatic patients (chest pain, dyspnea, palpitations, syncope/lipothymia) within 7 days of ICI administration
• New ECG abnormality (ST-segment elevation, ST-segment undershift, arrhythmia, conductive disturbances, T-wave inversion)
• Elevation of troponin above the 99th percentile of the laboratory reference value or, if troponin is already elevated before treatment, an increase of more than 30% of the baseline value
• Recent LVEF decline or recent LV contraction abnormality on a TTE
• Patient has given no objection Translated with www.DeepL.com/Translator (free version)

Exclusion Criteria:

• Age <18 years
• Major under guardianship or curatorship
• Pregnant or breastfeeding women
• Patient not covered by a social security plan
• Hemodynamic or rhythmic instability
• Estimation of glomerular filtration rate by the MDRD formula <30ml/min/1.73m2
• Implantable equipment that does not allow for cMRI

Related Conditions & MeSH terms

• Myocarditis

Locations

Country	Name	City	State
France	assistance publique hôpitaux de Marseille	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative incidence rate of the composite end point	including cardiovascular death, acute heart failure, cardiogenic shock, cardiac arrest, sustained ventricular tachycardia, ventricular fibrillation, 2nd-degree (except Mobitz 1) or 3rd-degree atrioventricular block.	6-month
Secondary	Cumulative incidence rate of all-cause death		6-month